nach oben

Urolithiasis

Erschienen in:

01.02.2016 | Invited Review

Metabolic risk-evaluation and prevention of recurrence in stone disease: does it make sense?

verfasst von: Hans-Göran Tiselius

Erschienen in: Urolithiasis | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

In this review, aspects on the importance of information on urine composition and selection of the most appropriate regimen for prevention of recurrence are discussed. For patients with urolithiasis the treatment is facilitated by urine analysis with estimates of supersaturation levels. Despite lack of strong scientific evidence for the benefit of selective versus non-selective prevention of recurrence in patients with calcium stone disease, there is currently both convincing and logical information in support of tailored/selective treatment regimens aiming at correction of abnormal target variables. Such an approach is also recommended in the EAU and AUA guidelines. It is important, however, that every preventive regimen is balanced between the effects on urine composition and patients’ tolerance to the treatment in order to achieve satisfactory compliance. It is possible that future improved understanding of the causes of calcium stone formation might provide a different therapeutic approach.

Trinchieri A, Dormia G, Montanari E, Zanetti G (2004) Cystinuria: definition, epidemiology and clinical aspects. Arch Ital Urol Androl 76:129–134PubMed

Ahlstrand C, Tiselius HG (1990) Recurrences during a 10-year follow-up after first renal stone episode. Urol Res 18:397–399CrossRefPubMed

Türk C, Knoll T, Petrik A, Sarica K, Skolarikos M, Straub M, Seitz C (2014) Guidelines on urolithiasis. In: European Association of Urology Guidelines. EAU Guidelines Office, Arnhem, The Netherlands

Leusmann D, Blaschke R, Schmandt W (1990) Result of 5,035 stone analyses: a contributionto epidemiology of urinary stone disease. Scand J Urol Nephrol 24:205–210CrossRefPubMed

Hering F, Lueoend G, Briellmann T, Seiler H, Guggenheim H, Rutishauser G (1988) Stone formation in the human kidney. In: Walker VR, Sutton RL, Cameron B, Pak CYC, Roberston WG (eds) Urolithiasis. Plenum Press, New York, pp 73–74

Tiselius H-G, Alken P, Buck C, Gallucci M, Knoll T, Sarica K, Türk C (2009) Guidelines on urolithiasis. In: European Association of Urology Guidelines. EAU Guidelines Office, Arnhem, The Netherlands

Cloutier J, Villa L, Traxer O, Daudon M (2015) Kidney stone analysis: “Give me your stone, I will tell you who you are!”. World J Urol 33:157–169PubMedCentralCrossRefPubMed

Brand E, Harris MM, Bildon S (1930) Cystinuria: excretion of a cystine complex which decomposes in the urine with liberation of free cystine. J Biol Chem 86:315

Hesse A, Tiselius H, Siener R, Hoppe R (2009) Crystals in the urinary sediment. In: Hesse A, Tiselius HG, Siener R, Hoppe B (eds.) Urinary stones, diagnosis, treatment and prevention of recurrence. Karger AG, Basel, pp 213–215

10.

Fogazzi GB (1996) Crystalluria: a neglected aspect of urinary sediment analysis. Nephrol Dial Transpl 11:379–387CrossRef

11.

Tiselius HG (2002) Medical evaluation of nephrolithiasis. Endocrinol Metab Clin North Am 31:1031–1050CrossRefPubMed

12.

Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petřík A, Türk C (2014) Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol S0302–2838:01102–01106

13.

Tiselius HG (1996) Solution chemistry of supersaturation. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones: medical and surgical management. Lippincott-Raven Publishers, Philadelphia, pp 33–64

14.

Evan AP, Coe FL, Lingeman JE, Shao Y, Sommer AJ, Bledsoe SB, Anderson JC, Worcester EM (2007) Mechanism of formation of human calcium oxalate renal stones on Randall’s plaque. Anat Rec 290:1315–1323CrossRef

15.

Tiselius H (2011) A hypothesis of calcium stone formation: an interpretation of stone research during the past decades. Urol Res 39:231–243CrossRefPubMed

16.

Tiselius HG (2015) Should we modify the principles of risk evaluation and recurrence preventive treatment of patients with calcium oxalate stone disease in view of the etiologic importance of calcium phosphate? Urolithiasis 43(Suppl 1):47–57CrossRefPubMed

17.

Khan SR, Canales BK (2015) Unified theory on the pathogenesis of Randall’s plaques and plugs. Urolithiasis 43(Suppl 1):109–123PubMedCentralCrossRefPubMed

18.

Tiselius HG (2011) A hypothesis of calcium stone formation: an interpretation of stone research during the past decades. Urol Res 39:231–243CrossRefPubMed

19.

Robertson WG (2003) A risk factor model of stone-formation. Front Biosci 8:s1330–s1338CrossRefPubMed

20.

Tiselius HG, Bek-Jensen H, Fornander AM, Nilsson MA (1995) Crystallisation properties in urine from calcium oxalate stone formers. J Urol 154:940–946CrossRefPubMed

21.

Heilberg IP, Goldfarb D (2013) Optimum nutrition for kidney stone disease. Adv Chronic Kidney Dis 20:165–174CrossRefPubMed

22.

Tiselius HG (2003) Epidemiology and medical management of stone disease. BJU Int 91:758–767CrossRefPubMed

23.

Fink H, Akornor J, Garimella P, Macdonald R, Cutting A, Rutks I, Monga M, Wilt T (2009) Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. Eur Urol 56:72—80PubMedCentralCrossRefPubMed

24.

Kocvara R, Plasgura P, Petrík A, Louzenský G, Bartonícková K, Dvorácek J (1999) A prospective study of nonmedical prophylaxis after a first kidney stone. BJU Int 84:393–398CrossRefPubMed

25.

Tiselius H-G, Alken P, Buck C, Gallucci M, Knoll T, Sarica K, Türk C (2009) EAU Guidelines on urolithiasis. In: European Association of Urology Guideline. EAU Guidelines Office, Arnhem, The Netherlands

26.

Ahlstrand C, Sandvall K, Tiselius HG (1995) Prophylactic treatment of calcium stone formers with hydrochlorothiazide and magnesium. In: Renal stones-aspects on their formation, removal and prevention. In: Tiselius HG (ed) Proceedings of the Sixth European Symposium on Urolithiasis. Linköping University, pp 195–197

27.

Elomaa I, Ala-Opas MLP (1984) Five years of experience with selective therapy in recurrent calcium nephrolithiasis. J Urol 132:656–661PubMed

28.

Brocks P, Dahl C, Wolf H, Transbøl I (1981) Do thiazides prevent recurrent idiopathic renal calcium stones? Lancet 18:124–125CrossRef

29.

Ettinger B, Tang A, Citron JT, Livermore B, Williams T (1986) Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 27:1386–1389CrossRef

30.

Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, Brasure M, Kane RL, Monga M (2013) Recurrent nephrolithiasis in adults: comparative effectiveness of preventive medical strategies, Number 61 Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Jul. AHRQ Publication No. 12-EHC049-EF

31.

Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD, Clinical Guidelines Committee of the American College of Physicians (2014) Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med 16:659–667CrossRef

32.

Pearle MS, Roehrborn CG, Pak CY (1999) Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 13:679–685CrossRefPubMed

33.

Robertson WG (2006) Is prevention of stone recurrence financially worthwhile? Urol Res 34:157–161CrossRefPubMed

34.

Yendt ER, Guay GF, Garcia DA (1970) The use of thiazides in the prevention of renal calculi. Can Med Assoc J 102:614–620PubMedCentralPubMed

35.

Yendt ER, Cohanim M (1978) Prevention of calcium stones with thiazides. Kidney Int 13:397–409CrossRefPubMed

36.

Ala-Opas M, Elomaa I, Porkka L, Alfthan O (1987) Unprocessed bran and intermittent thiazide therapy in prevention of recurrent urinary calcium stones. Scand J Urol Nephrol 21:311–314CrossRefPubMed

37.

Tiselius HG, Larsson L, Hellgren E (1986) Clinical results of allopurinol treatment in prevention of calcium oxalate stone formation. J Urol 136:5–53

38.

Ahlstrand C, Tiselius HG, Larsson L, Hellgren E (1984) Clinical experience with long-term bendroflumethiazide treatment in calcium oxalate stone formers. Br J Urol 56:255–262CrossRefPubMed

39.

Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR, Association AUA (2014) Medical management of kidney stones: AUA guideline. J Urol 192:316–324CrossRefPubMed

40.

Parks JH, Coe FL (2009) Evidence for durable kidney stone prevention over several decades. BJU Int 103:1238–1246PubMedCentralCrossRefPubMed

41.

Bek-Jensen H, Tiselius HG (1989) Stone formation and urine composition in calcium stone formers without medical treatment. Eur Urol 16:144–150PubMed

42.

Tiselius HG (1999) Factors influencing the course of calcium oxalate stone disease. Eur Urol 36:363–370CrossRefPubMed

43.

Tiselius H-G (1989) Standardized estimate of the ion-activity product of calcium oxalate in urine from renal stone formers. Eur Urol 16:48–50PubMed

44.

Tiselius HG (2005) Aetiological factors in stone formation. In: Davison AM, Cameron JS, Grünfeld J-P, Ritz E, Winearls CG, van Ypersele C (eds) Oxford textbook of clinical nephrology, 3rd edn. Oxford University Press, Oxford, pp 1199–1223

45.

Ahlstrand C, Tiselius HG (1987) Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol 21:225–228CrossRefPubMed

46.

Muldowney FP, Freaney R, Moloney MF (1982) Importance of dietary sodium in the hypercalciuria syndrome. Kidney Int 22:292–296CrossRefPubMed

47.

Taylor EN, Curhan GC (2006) Diet and fluid prescription in stone disease. Kidney Int 70:835–839CrossRefPubMed

Titel: Metabolic risk-evaluation and prevention of recurrence in stone disease: does it make sense?
verfasst von: Hans-Göran Tiselius
Publikationsdatum: 01.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Urolithiasis / Ausgabe 1/2016
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-015-0840-y

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Metabolic risk-evaluation and prevention of recurrence in stone disease: does it make sense?

Abstract

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Fehlerkultur in der Medizin – Offenheit zählt!

Update Urologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Can the manipulation of urinary pH by beverages assist with the prevention of stone recurrence?

The management of patients with enteric hyperoxaluria

The exposome for kidney stones

Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?

The preventive treatment of recurrent stone-formation: how can we improve compliance in the treatment of patients with recurrent stone disease?

Preface

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Fehlerkultur in der Medizin – Offenheit zählt!

Update Urologie